The Combined Inducible Nitric Oxide Synthase Inhibitor and Free Radical Scavenger Guanidinoethyldisulfide Prevents Multiple Low-Dose Streptozotocin-Induced Diabetes In Vivo and Interleukin-1β-Induced Suppression of Islet Insulin Secretion In Vitro

Pancreas

Volumn 28, Issue 2, 2004, Pages

  Mabley, Jon G ^a   Southan, Gary J ^a   Salzman, Andrew L ^a   Szabó, Csaba ^a  

^a INOTEK CORPORATION   (United States)

Author keywords

Cytokines; Diabetes; Nitric oxide; Peroxynitrite; Streptozotocin

Indexed keywords

BIS(2 GUANIDINOETHYL) DISULFIDE; BIS(2-GUANIDINOETHYL)DISULFIDE; ENZYME INHIBITOR; GUANIDINE DERIVATIVE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; INTERLEUKIN 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NITRIC OXIDE SYNTHASE; NOS2 PROTEIN, MOUSE; NOS2 PROTEIN, RAT; SCAVENGER; STREPTOZOCIN;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; INSULIN DEPENDENT DIABETES MELLITUS; MALE; METABOLISM; MOUSE; PANCREAS ISLET; RAT; SECRETION;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ENZYME INHIBITORS; FREE RADICAL SCAVENGERS; GUANIDINES; INSULIN; INTERLEUKIN-1; ISLETS OF LANGERHANS; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; POLY(ADP-RIBOSE) POLYMERASES; RATS; STREPTOZOCIN;

EID: 4844229186     PISSN: 08853177     EISSN: 15364828     Source Type: Journal    
DOI: 10.1097/00006676-200403000-00018     Document Type: Article

References (48)

1. Noorchashm H, Kwok W, Rabinovitch A, et al. Immunology of IDDM. Diabetologia. 1997; 40(suppl 3):B50-B57.
2. Rabinovitch A. Immunoregulatory and cytokine imbalances in the pathogenesis of IDDM. Therapeutic intervention by immunostimulation? Diabetes. 1994; 43:613-621.
3. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol. 1998; 55:1139-1149.
4. Rabinovitch A. An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1998; 14:129-151.
5. Southern C, Schulster D, Green IC. Inhibition of insulin secretion by interleukin-1β and tumour necrosis factor-α by an L-arginine-dependent nitric oxide generating mechanism. FEBS Lett. 1990; 276:42-44.
6. Corbett JA, McDaniel ML. Does nitric oxide mediate autoimmune destruction of β-cells? Possible therapeutic interventions in IDDM. Diabetes. 1992; 41:897-903.
7. Lakey JR, Suarez-Pinzon WL, Strynadka K, et al. Peroxynitrite is a mediator of cytokine-induced destruction of human pancreatic islet β cells. Lab Invest. 2001; 81:1683-1692.
8. Suarez-Pinzon WL, Szabo C, Rabinovitch A. Development of autoimmune diabetes in NOD mice is associated with the formation of peroxynitrite in pancreatic islet β-cells. Diabetes. 1997; 46:907-911.
9. Suarez-Pinzon WL, Mabley JG, Strynadka K, et al. An inhibitor of inducible nitric oxide synthase and scavenger of peroxynitrite prevents diabetes development in nod mice. J Autoimmun. 2001; 16:449-455.
10. Garcia Soriano F, Virag L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med. 2001; 7:108-113.
11. Bradford MM. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248-254.
12. Liaudet L, Mabley JG, Soriano FG, et al. Inosine reduces systemic inflammation and improves survival in septic shock induced by cecal ligation and puncture. Am J Respir Crit Care Med. 2001; 164:1213-1220.
13. Mabley JG, Pacher P, Liaudet L, et al. Inosine reduces inflammation and improves survival in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2003; 284:G138-G144.
14. Mabley J, Soriano F, Pacher P, et al. The adenosine A(3) receptor agonist, N(6)-(3-iodobenzyl)-adenosine-5′-N-methyluronamide, is protective in two murine models of colitis. Eur J Pharmacol. 2003; 466:323-329.
15. Mabley JG, Pacher P, Southan GJ, et al. Nicotine reduces the incidence of type I diabetes in mice. J Pharmacol Exp Ther. 2002; 300:876-881.
16. Mabley JG, John NE, Green IC. Transforming growth factor β1 reverses cytokine-mediated inhibition of protein synthesis and loss of cell viability in RINm5F cells and prevents induction of nitric oxide synthase. J Endocrinol. 1996; 148:P100.
17. Mabley JG, Schulster D, Green IC. Insulin-like growth factor 1 protects rat islet insulin secretion from interleukin-1β inhibition. Diabetologia. 1995; 38:A80.
18. Gey GO, Gey MH. Maintenance of human normal cells and tumour cells in continuous culture. Am J Cancer. 1936; 27:45-76.
19. Mabley JG, Suarez-Pinzon WL, Hasko G, et al. Inhibition of poly (ADP-ribose) synthetase by gene disruption or inhibition with 5-iodo-6-amino-1,2-benzopyrone protects mice from multiple-low-dose-streptozotocin-induced diabetes. Br J Pharmacol. 2001; 133:909-919.
20. Mabley JG, Hasko G, Liaudet L, et al. NFkappaB1 (p50)-deficient mice are not susceptible to multiple low-dose streptozotocin-induced diabetes. J Endocrinol. 2002; 173:457-464.
21. Szabo C, Virag L, Cuzzocrea S, et al. Protection against peroxynitrite-induced fibroblast injury and arthritis development by inhibition of poly(ADP-ribose) synthase. Proc Natl Acad Sci U S A. 1998; 95:3867-3872.
22. Mabley JG, Belin V, John N, et al. Insulin-like growth factor I reverses interleukin-1β inhibition of insulin secretion, induction of nitric oxide synthase and cytokine-mediated apoptosis in rat islets of Langerhans. FEBS Lett. 1997; 417:235-238.
23. Mabley JG, Cunningham JM, John N, et al. Transforming growth factor β 1 prevents cytokine-mediated inhibitory effects and induction of nitric oxide synthase in the RINm5F insulin-containing β-cell line. J Endocrinol. 1997; 155:567-575.
24. Eizirik DL, Flodstrom M, Karlsen AE, et al. The harmony of the spheres: inducible nitric oxide synthase and related genes in pancreatic β cells. Diabetologia. 1996; 39:875-890.
25. Cunningham JM, Mabley JG, Delaney CA, et al. The effect of nitric oxide donors on insulin secretion, cyclic GMP and cyclic AMP in rat islets of Langerhans and the insulin-secreting cell lines HIT-T15 and RINm5F. Mol Cell Endocrinol. 1994; 102:23-29.
26. Di Matteo MA, Loweth AC, Thomas S, et al. Superoxide, nitric oxide, peroxynitrite and cytokine combinations all cause functional impairment and morphological changes in rat islets of Langerhans and insulin-secreting cell lines but dictate cell death by different mechanisms. Apoptosis. 1997; 2:164-177.
27. Andersson AK, Flodstrom M, Sandler S. Cytokine-induced inhibition of insulin release from mouse pancreatic β-cells deficient in inducible nitric oxide synthase. Biochem Biophys Res Commun. 2001; 281:396-403.
28. Corbett JA, Mikhael A, Shimizu J, et al. Nitric oxide production in islets from nonobese diabetic mice: aminoguanidine-sensitive and-resistant stages in the immunological diabetic process. Proc Natl Acad Sci U S A. 1993; 90:8992-8995.
29. Lindsay RM, Smith W, Rossiter SP, et al. Baird, JD, NW-nitro-L-arginine methyl ester reduces the incidence of IDDM in BB/E rats. Diabetes. 1995; 44:365-368.
30. G-monomethyl-L-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes. 1995; 44:360-364.
31. Flodstrom M, Tyrberg B, Eizirik DL, et al. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes. 1999; 48:706-713.
32. Holstad M, Sandler S. Aminoguanidine, an inhibitor of nitric oxide formation, fails to protect against insulitis and hyperglycemia induced by multiple low dose streptozotocin injections mice. Autoimmunity. 1993; 15:311-314.
33. Papaccio G, Esposito V, Latronico MV, et al. Administration of a nitric oxide synthase inhibitor does not suppress low-dose streptozotocin-induced diabetes in mice. Int J Pancreatol. 1995; 17:63-68.
34. Sternesjo J, Welsh N, Sandler S. S-methyl-L-thiocitrulline counteracts interleukin 1 β induced suppression of pancreatic islet function in vitro, but does not protect against multiple low-dose streptozotocin-induced diabetes in vivo. Cytokine. 1997; 9:352-359.
35. Rydgren T, Sandler S. Efficacy of 1400 W, a novel inhibitor of inducible nitric oxide synthase, in preventing interleukin-1β-induced suppression of pancreatic islet function in vitro and multiple low-dose streptozotocin-induced diabetes in vivo. Eur J Endocrinol. 2002; 147:543-551.
36. Cunningham JM, Green IC. Cytokines, nitric oxide and insulin secreting cells. Growth Regul. 1994; 4:173-180.
37. Szabó C, Mabley JG, Moeller SM, et al. Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med. 2002; 8:571-580.
38. Heller B, Burkle A, Radons J, et al. Analysis of oxygen radical toxicity in pancreatic islets at the single cell level. Biol Chem Hoppe Seyler. 1994; 375:597-602.
39. Mendola J, Wright JRJ, Lacy PE. Oxygen free-radical scavengers and immune destruction of murine islets in allograft rejection and multiple low-dose streptozocin-induced insulitis. Diabetes. 1989; 38:379-385.
40. Sandler S, Andersson A. The partial protective effect of the hydroxyl radical scavenger dimethyl urea on streptozotocin-induced diabetes in the mouse in vivo and in vitro. Diabetologia. 1982; 23:374-378.
41. Lenzen S, Drinkgern J, Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic Biol Med. 1996; 20:463-466.
42. MacMillan-Crow LA, Crow JP, Kerby JD, et al. Thompson, JA, Nitration and inactivation of manganese superoxide dismutase in chronic rejection of human renal allografts. Proc Natl Acad Sci U S A. 1996; 93:11853-11858.
43. MacMillan-Crow LA, Crow JP, Thompson JA. Peroxynitrite-mediated inactivation of manganese superoxide dismutase involves nitration and oxidation of critical tyrosine residues. Biochemistry (Mosc). 1998; 37:1613-1622.
44. Kocis JM, Kuo WN, Liu Y, et al. Regulation of catalase: inhibition by peroxynitrite and reactivation by reduced glutathione and glutathione S-transferase. Front Biosci. 2002; 7:a175-a180.
45. Hohmeier HE, Thigpen A, Tran VV, et al. Stable expression of manganese superoxide dismutase (MnSOD) in insulinoma cells prevents IL-1β-induced cytotoxicity and reduces nitric oxide production. J Clin Invest. 1998; 101:1811-1820.
46. Lortz S, Tiedge M, Nachtwey T, et al. Protection of insulin-producing RINm5F cells against cytokine-mediated toxicity through overexpression of antioxidant enzymes. Diabetes. 2000; 49:1123-1130.
47. Azevedo-Martins AK, Lortz S, Lenzen S, et al. Improvement of the mitochondrial antioxidant defense status prevents cytokine-induced nuclear factor-kappaB activation in insulin-producing cells. Diabetes. 2003; 52:93-101.
48. Bertera S, Crawford ML, Alexander AM, et al. Gene transfer of manganese superoxide dismutase extends islet graft function in a mouse model of autoimmune diabetes. Diabetes. 2003; 52:387-393.